Frontier Bio Corp — SEC Form D Filing

Frontier Bio Corp filed an SEC Form D on November 10, 2026, reporting $380K raised in Regenerative Medicine.

Form D filing details

Filing
SEC Form D
Filing date
November 10, 2026
Amount reported
$380K
Round stage
Seed
Industry
Regenerative Medicine
Website
https://www.frontierbio.com/

What the company does

Securities: Simple Agreement for Future Equity (SAFE), convertible into preferred stock. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Surgeons needing replacement blood vessels currently rely on synthetic grafts that carry a high risk of clotting, or on harvesting a patient's own veins, which adds surgical time, creates a second wound, and is not an option for patients lacking suitable spare veins.

Solution

Frontier Bio develops living vascular grafts made by seeding a dissolvable scaffold with cells extracted from a patient's fat sample, enabling implantation during the same surgery to regenerate a natural living vessel.

Why now

Advances in bioresorbable materials and intraoperative cell-isolation techniques make it feasible to seed and implant tissue-engineered grafts within a single surgical procedure.

Verdict

This cleared because the clinical misery of synthetic graft failure is undisputed, not because the company proved a point-of-care cellular workflow scales economically. Investors backed the thesis that an intraoperative autologous graft sidesteps the severe immunogenicity and cold-chain distribution baggage weighing down acellular tissue competitors. They were implicitly betting that vascular surgeons would trade operating-room convenience for superior long-term patency. However, the micro-raise ($380,000) signals heavy investor hesitation around surgical friction, regulatory combination-product classification, and the questionable economics of custom, chairside biomanufacturing.

Source: SEC EDGAR Form D filing